Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s10067-020-05529-y http://scihub22266oqcxt.onion/10.1007/s10067-020-05529-y 33411143!7788381!33411143     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Rheumatol 2021 ; 40 (2): 433-442 Nephropedia Template TP {{tp|p=33411143|t=2021. COVID-19, rheumatic diseases and immune dysregulation-a perspective |pdf=|usr=}}{{33411143}} gab.com Text COVID-19, rheumatic diseases and immune dysregulation-a perspective JO: Clin Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=33411143 #FOAvip The COVID-19 pandemic has resulted in widespread hospitalisations and deaths around the world. As patients with rheumatic diseases generally have increased risk of infections and complications, understandably, there is significant concern of the impact of SARS-CoV-2 on these patients. However, there is a paucity of data in rheumatic patients. We review mechanisms through which SARS-CoV-2 results in infection, including ACE2 receptor, and complications (including immune dysregulation, thrombosis and complement activation). We assess these pathways in patients with rheumatic disease and those on immune modulating therapy. Although data thus far does not appear to show worse outcomes in rheumatic patients as a whole, given alterations in the underlying immune pathways in certain diseases (such as systemic lupus erythematosus), we posit that the risk is not equal in all rheumatic patients. We also discuss the benefit of underlying disease control with respect to COVID-19 risk reduction and potential increased risk of disease flares following viral infection from an immune standpoint. Twit Text FOAVip COVID-19, rheumatic diseases and immune dysregulation-a perspective ????Clin Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=33411143 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33411143 #FOAvip English Wikipedia <ref>{{Cite pmid|33411143}}</ref> COVID-19, rheumatic diseases and immune dysregulation-a perspective #MMPMID33411143 Tariq S; Van Eeden C; Tervaert JWC; Osman MS Clin Rheumatol 2021[Feb]; 40 (2): 433-442 PMID33411143show ga The COVID-19 pandemic has resulted in widespread hospitalisations and deaths around the world. As patients with rheumatic diseases generally have increased risk of infections and complications, understandably, there is significant concern of the impact of SARS-CoV-2 on these patients. However, there is a paucity of data in rheumatic patients. We review mechanisms through which SARS-CoV-2 results in infection, including ACE2 receptor, and complications (including immune dysregulation, thrombosis and complement activation). We assess these pathways in patients with rheumatic disease and those on immune modulating therapy. Although data thus far does not appear to show worse outcomes in rheumatic patients as a whole, given alterations in the underlying immune pathways in certain diseases (such as systemic lupus erythematosus), we posit that the risk is not equal in all rheumatic patients. We also discuss the benefit of underlying disease control with respect to COVID-19 risk reduction and potential increased risk of disease flares following viral infection from an immune standpoint. |*Autoimmunity[MESH] |*Pandemics[MESH] |*SARS-CoV-2[MESH] |Autoimmune Diseases/*epidemiology/immunology[MESH] |COVID-19/*epidemiology[MESH] |Humans[MESH]COVID-19, rheumatic diseases and immune dysregulation-a perspective (epmc).pdf DeepDyve Pubget Overpricing